Connor, Clark & Lunn Investment Management (CC&L)
CORT icon

Connor, Clark & Lunn Investment Management (CC&L)’s Corcept Therapeutics CORT Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.09M Sell
81,569
-36,385
-31% -$2.2M 0.01% 629
2026
Q1 		$4.75M Sell
117,954
-103,490
-47% -$3.87M 0.01% 698
2025
Q4 		$7.71M Sell
221,444
-148,425
-40% -$11.7M 0.02% 530
2025
Q3 		$30.7M Buy
369,869
+51,864
+16% +$3.75M 0.1% 194
2025
Q2 		$23.3M Sell
318,005
-433,213
-58% -$31.4M 0.08% 216
2025
Q1 		$85.8M Sell
751,218
-45,577
-6% -$2.77M 0.37% 50
2024
Q4 		$40.2M Sell
796,795
-62,768
-7% -$3.29M 0.18% 99
2024
Q3 		$39.8M Buy
859,563
+143,507
+20% +$5.1M 0.19% 85
2024
Q2 		$23.3M Buy
716,056
+173,878
+32% +$4.76M 0.1% 169
2024
Q1 		$13.7M Buy
542,178
+180,971
+50% +$4.28M 0.06% 254
2023
Q4 		$11.7M Sell
361,207
-1,229
-0.3% -$33.7K 0.05% 253
2023
Q3 		$9.87M Sell
362,436
-472
-0.1% -$13.7K 0.05% 250
2023
Q2 		$8.07M Buy
362,908
+141,896
+64% +$3.27M 0.04% 300
2023
Q1 		$4.79M Buy
221,012
+82,269
+59% +$1.8M 0.03% 378
2022
Q4 		$2.82M Buy
138,743
+56,445
+69% +$1.41M 0.02% 468
2022
Q3 		$2.11M Buy
82,298
+7,634
+10% +$204K 0.01% 488
2022
Q2 		$1.78M Sell
74,664
-62,886
-46% -$1.37M 0.01% 495
2022
Q1 		$3.1M Buy
137,550
+89,449
+186% +$1.9M 0.02% 406
2021
Q4 		$952K Buy
48,101
+36,251
+306% +$735K ﹤0.01% 686
2021
Q3 		$233K Buy
+11,850
New +$248K ﹤0.01% 924

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s CORT Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) reduced its Corcept Therapeutics (CORT) stake by 31% in Q2 2026, selling an estimated $2.2M and leaving 81,569 shares worth $7.09M. The position accounts for 0.01% of the portfolio, ranked #629.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in CORT in Q3 2021 and has held it in 20 quarters since. The position peaked at $85.8M in Q1 2025. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) held 81,569 shares of Corcept Therapeutics worth $7.09M as of Q2 2026.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 36,385 Corcept Therapeutics shares in Q2 2026, an estimated $2.2M.
  • Corcept Therapeutics made up 0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #629 holding.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Corcept Therapeutics in Q3 2021 and has held it in 20 quarters since.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Corcept Therapeutics position peaked at $85.8M in Q1 2025.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.